Microbot Medical is transitioning from R&D to commercialization with its LIBERTY single-use robotic system for endovascular interventions. I assign MBOT a neutral rating with a 1-year price target of ...

Commence the Full Market Release (FMR) of the LIBERTY System in Q2 2026, in conjunction with the Society of Interventional Radiology (SIR) conference. Grow customer base by attracting early adopters ...

Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 434.50% Upside As of ...

We recently published 10 Stocks Losing Big Amid Market Boom. Microbot Medical Inc. (NASDAQ:MBOT) is one of the worst performers on Thursday. Microbot extended its losing streak to a fourth consecutive ...

Shares of Microbot Medical (NASDAQ:MBOT) rose in the premarket on Wednesday after the MedTech firm announced that a pivotal trial for its Liberty endovascular surgical robotic system reached the ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Microbot Medical Inc (NASDAQ:MBOT) stands ...

A new study has found evidence of big gains in students’ reading ability from using one specific phonics program—and suggests that consistent implementation is key to getting the strongest results.

Microbot Medical (MBOT) is continuing its transition into a commercially focused company with the election of David Wilson to the Board of Directors. David is currently the CEO of InnovHeart, an ...

Microbot Medical (MBOT) announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the ...

Microbot Medical Inc (NASDAQ:MBOT) shares are trading higher by 22% to $2.58 during Monday’s session after the company announced it sold 4.26 million shares under an ATM agreement and generated $4.82 ...